News - Licensing


Current filters:


Popular Filters

201 to 225 of 961 results

Ferrer and Medivir join forces on Adasuve for Nordic markets


Sweden’s Medivir (Nasdaq OMX: MVIR) and privately-held Spanish drugmaker Ferrer Internacional have…

AdasuveAlexza PharmaceuticalEuropeFerrer InternacionalLicensingMedivirNeurologicalPharmaceutical

GlaxoSmithKline returns rights to vercirnon


US drug developer ChemoCentryx (Nasdaq: CCXI) says that partner GlaxoSmithKline (LSE: GSK), the UK’s…

ChemoCentryxGastro-intestinalsGlaxoSmithKlineLicensingNorth AmericaPharmaceuticalvercirnon

Cardiome in deal for commercialization of Brinavess in Israel


Canada-based Cardiome Pharma (TSX: COM) has entered into an agreement with Tzamal Medical to sell and…

BrinavessCardio-vascularCardiome PharmaLicensingPharmaceuticalRest of the WorldTzamal Medical

Takeda out-licenses Edarbi and Edarbyclor


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into a license, development and…

Arbor PharmaceuticalsCardio-vascularEdarbiEdarbyclorLicensingNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Valneva enters deals with Delta-Vir


Biotech firm Valneva (Euronext: VLA), the company recently created through the merger of France's Vivalis…


Roche in up to $422.5 million deal with Inovio Pharma


Swiss drug major Roche (ROG: SIX) has signed an exclusive, worldwide license agreement with US drug developer…

Anti-viralsINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

AstraZeneca gains rights to Merck ovarian cancer candidate


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US pharma giant Merck & Co (NYSE: MRK) this morning…

AstraZenecaLicensingMerck & CoMK-1775OncologyPharmaceutical

Biogen Idec in deal with Amicus for Parkinson's disease


US biotech firm Amicus Therapeutics (Nasdaq: FOLD) has entered a collaboration with Biogen Idec (Nasdaq:…

Amicus TherapeuticsBiogen IdecBiotechnologyLicensingNeurologicalResearch

Bayer enters a further academic collaboration on innovative cancer therapies


In a further collaboration with academia, German pharma and chemical major Bayer (BAYN: DE) has entered…


Depomed expands geographic scope of metformin deal with Merck


USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

Biogen Idec and Isis Pharma collaborate in $100 million upfront deal


US biotech firms Biogen Idec (Nasdaq: BIIB) and Isis Pharmaceuticals (Nasdaq: ISIS) have entered into…

Biogen IdecBiotechnologyIsis PharmaceuticalsLicensingNeurologicalResearch

DRI Capital raises $1.45 billion for Drug Royalty III


DRI Capital, a global leader in the acquisition of health care royalties, today (September 9) announced…


SOBI restructures Kineret and Kepivance deals


Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

Novartis links with Regenerex in cell therapy research collaboration


Swiss drug major Novartis (NOVN: VX) has entered into an exclusive global licensing and research collaboration…


Karo Bio gets first milestone in Pfizer collaboration


Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

ThromboGenics gains rights to DME drug


Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Kyowa Hakko Kirin collaborates with Ultragenyx on KRN23


Japanese mid-sized drugmaker Kyowa Hakko Kirin (TYO: 4151) has entered into a collaboration and license…

BiotechnologyKRN23Kyowa Hakko KirinLicensingPharmaceuticalRare diseasesResearchUltragenyx

Repligen gets first milestone under SMA deal with Pfizer


USA-based Repligen (Nasdaq: RGEN) says it has received a $1 million milestone payment from global drugs…

FinancialLicensingPfizerPharmaceuticalRare diseasesRepligen

Sanofi US in deal to commercialize PA8140/PA32540


The US subsidiary of French drug major Sanofi (Euronext: SAN) has entered into a deal with US drugmaker…

AspirinCardio-vascularGastro-intestinalsLicensingNorth AmericaOmeprazolePharmaceuticalPozenSanofi

Syndax and Eddingpharm collaborate on entinostat


Privately-held US epigenetics firm Syndax Pharmaceuticals and Eddingpharm, a leading specialty pharmaceutical…

Asia-PacificentinostatLicensingOncologyPharmaceuticalSyndax Pharmaceuticals

Tris Pharma and FSC Labs enter Karbinal accord


Drug delivery specialist Tris Pharma and fellow USA-based privately-held company FSC Laboratories have…

FSC LaboratoriesKarbinalLicensingNorth AmericaPharmaceuticalRespiratory and PulmonaryTris Pharma

Baxter and Coherus in up to $246 million deal for biosimilar etanercept


US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

Santhera regains Catena European rights


Switzerland-based Santhera Pharmaceuticals (SIX: SANN) says that it has reached an agreement with Takeda…

CatenaEuropeLicensingPharmaceuticalRare diseasesSanthera PharmaceuticalsTakeda Pharmaceuticals

201 to 225 of 961 results

Back to top